- Home
- A-Z Publications
- Current Drug Targets-CNS & Neurological Disorders
- Previous Issues
- Volume 4, Issue 3, 2005
Current Drug Targets-CNS & Neurological Disorders - Volume 4, Issue 3, 2005

Volume 4, Issue 3, 2005
-
-
The Neuroinflammatory Response in Plaques and Amyloid Angiopathy in Alzheimer's Disease: Therapeutic Implications
Authors: Annemieke J.M. Rozemuller, Willem A van Gool and Piet EikelenboomThe amyloid plaques in Alzheimer's disease (AD) brains are co-localised with a broad variety of inflammation-related proteins (complement proteins, acute-phase proteins, pro-inflammatory cytokines) and clusters of activated microglia. The present data suggest that the Aβ depositions in the neuroparenchyma are closely associated with a locally-induced, non-immune-mediated chronic inflammatory response. Clinicopath Read More
-
-
-
Amyloid Associated Proteins in Alzheimer's and Prion Disease
Authors: R. Veerhuis, R. S. Boshuizen and A. FamilianClustering of activated microglia in Aβ deposits is related to accumulation of amyloid associated factors and precedes the neurodegenerative changes in AD. Microglia-derived pro-inflammatory cytokines are suggested to be the driving force in AD pathology. Inflammation-related proteins, including complement factors, acute-phase proteins, pro-inflammatory cytokines, that normally are locally produced at low levels, are in Read More
-
-
-
Preventing Activation of Receptor for Advanced Glycation Endproducts in Alzheimer's Disease
Authors: L- F. Lue, S. D. Yan, D. M. Stern and D. G. WalkerReceptor for advanced glycation endproducts (RAGE), a member of the immunoglobulin superfamily, is a multi-ligand, cell surface receptor expressed by neurons, microglia, astrocytes, cerebral endothelial cells, pericytes, and smooth muscle cells. At least three major types of the RAGE isoforms (full length, C-truncated, and N-truncated) are present in human brains as a result of alternative splicing. Differential expressio Read More
-
-
-
The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders
Authors: Freek L. van Muiswinkel and H. B. KuiperijA large body of evidence indicates that oxidative stress is a salient pathological feature in many neurodegenerative diseases, including Amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease. In addition to signs of systemic oxidative stress, at the biochemical and neuropathological level, neuronal degeneration in these disorders has been shown to coincide with several markers of oxidative damage Read More
-
-
-
Protein Quality Control in Alzheimer's Disease: A Fatal Saviour
Authors: W. Scheper and E. M. HolAggregation of Aβ plays a key role in the pathogenesis of Alzheimer's disease. Although the highly structured Aβ aggregates (fibrils) have long been thought to be the toxic form of Aβ, recent evidence suggests that smaller, soluble intermediates in Ab aggregation are the real culprit. Because these oligomeric aggregates are already formed in the secretory pathway, this raises another issue: Is intra- or extracellular Aβ involved Read More
-
-
-
The Expression of Cell Cycle Proteins in Neurons and its Relevance for Alzheimer's Disease
Authors: Uwe Ueberham and Thomas ArendtAlzheimer's disease is a chronic neurodegenerative disorder characterised by typical pathological hallmarks such as amyloid deposition, neurofibrillary tangles and disturbances in the expression of various cell cycle proteins. A current pathogenetic hypothesis suggests that neurons, forced by external and internal factors, leave the differentiated G0 phase and re-enter the cell cycle. This process results in neuronal de Read More
-
-
-
The Role of COX-1 and COX-2 in Alzheimer's Disease Pathology and the Therapeutic Potentials of Non-Steroidal Anti-Inflammatory Drugs
Authors: Jeroen J.M. Hoozemans and M. K. O'BanionEpidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal antiinflammatory drugs (NSAIDs), decrease the risk of developing Alzheimer's disease (AD). Their beneficial effects may be due to interference of the chronic inflammatory reaction in AD. The best-characterised action of NSAIDs is the inhibition of cyclooxygenase (COX). So far, clinical trials designed to inhibit inflammation or cycloox Read More
-
Volumes & issues
Most Read This Month
Article
content/journals/cdtcnsnd
Journal
10
5
false
en
